Terms: = Ovarian cancer AND uPA AND Prognosis
32 results:
1. ALG3 Promotes Peritoneal Metastasis of ovarian cancer through Increasing Interaction of α1,3-mannosylated upaR and ADAM8.
Cui X; Pei X; Wang H; Feng P; Qin H; Liu S; Yan Q; Liu J
Cells; 2022 Oct; 11(19):. PubMed ID: 36231102
[TBL] [Abstract] [Full Text] [Related]
2. Downregulation of SPINK13 Promotes Metastasis by Regulating upa in ovarian cancer Cells.
Cai S; Zhang P; Dong S; Li L; Cai J; Xu M
Cell Physiol Biochem; 2018; 45(3):1061-1071. PubMed ID: 29439245
[TBL] [Abstract] [Full Text] [Related]
3. cRGD inhibits vasculogenic mimicry formation by down-regulating upa expression and reducing EMT in ovarian cancer.
Tang J; Wang J; Fan L; Li X; Liu N; Luo W; Wang J; Wang Y; Wang Y
Oncotarget; 2016 Apr; 7(17):24050-62. PubMed ID: 26992227
[TBL] [Abstract] [Full Text] [Related]
4. Biomarkers in Breast cancer: Where Are We and Where Are We Going?
Duffy MJ; Walsh S; McDermott EW; Crown J
Adv Clin Chem; 2015; 71():1-23. PubMed ID: 26411409
[TBL] [Abstract] [Full Text] [Related]
5. Expression and activity analysis of a new fusion protein targeting ovarian cancer cells.
Su M; Chang W; Wang D; Cui M; Lin Y; Wu S; Xu T
Oncol Rep; 2015 Sep; 34(3):1337-44. PubMed ID: 26166362
[TBL] [Abstract] [Full Text] [Related]
6. Tissue invasion and metastasis: Molecular, biological and clinical perspectives.
Jiang WG; Sanders AJ; Katoh M; Ungefroren H; Gieseler F; Prince M; Thompson SK; Zollo M; Spano D; Dhawan P; Sliva D; Subbarayan PR; Sarkar M; Honoki K; Fujii H; Georgakilas AG; Amedei A; Niccolai E; Amin A; Ashraf SS; Ye L; Helferich WG; Yang X; Boosani CS; Guha G; Ciriolo MR; Aquilano K; Chen S; Azmi AS; Keith WN; Bilsland A; Bhakta D; Halicka D; Nowsheen S; Pantano F; Santini D
Semin Cancer Biol; 2015 Dec; 35 Suppl():S244-S275. PubMed ID: 25865774
[TBL] [Abstract] [Full Text] [Related]
7. Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer.
Mashiko S; Kitatani K; Toyoshima M; Ichimura A; Dan T; Usui T; Ishibashi M; Shigeta S; Nagase S; Miyata T; Yaegashi N
Cancer Biol Ther; 2015; 16(2):253-60. PubMed ID: 25587663
[TBL] [Abstract] [Full Text] [Related]
8. Ki-67 as an independent prognostic factor in an unselected cohort of patients with ovarian cancer: results of an explorative, retrospective study.
Battista MJ; Mantai N; Sicking I; Cotarelo C; Weyer V; Lebrecht A; Solbach C; Schmidt M
Oncol Rep; 2014 May; 31(5):2213-9. PubMed ID: 24627004
[TBL] [Abstract] [Full Text] [Related]
9. [Clinical prospects of tumor-associated proteases and their tissue inhibitors investigation in oncologic patient].
Gershteĭn ES; Kushlinskiĭ NE
Vestn Ross Akad Med Nauk; 2013; (5):16-27. PubMed ID: 24000664
[TBL] [Abstract] [Full Text] [Related]
10. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract] [Full Text] [Related]
11. Loss of SerpinA5 protein expression is associated with advanced-stage serous ovarian tumors.
Bijsmans IT; Smits KM; de Graeff P; Wisman GB; van der Zee AG; Slangen BF; de Bruïne AP; van Engeland M; Sieben NL; Van de Vijver KK
Mod Pathol; 2011 Mar; 24(3):463-70. PubMed ID: 21102419
[TBL] [Abstract] [Full Text] [Related]
12. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
[TBL] [Abstract] [Full Text] [Related]
13. Activated platelets enhance ovarian cancer cell invasion in a cellular model of metastasis.
Holmes CE; Levis JE; Ornstein DL
Clin Exp Metastasis; 2009; 26(7):653-61. PubMed ID: 19444623
[TBL] [Abstract] [Full Text] [Related]
14. Estradiol attenuates EGF-induced rapid upaR mobilization and cell migration via the G-protein-coupled receptor 30 in ovarian cancer cells.
Henic E; Noskova V; Høyer-Hansen G; Hansson S; Casslén B
Int J Gynecol Cancer; 2009 Feb; 19(2):214-22. PubMed ID: 19395996
[TBL] [Abstract] [Full Text] [Related]
15. [Expression and clinical significance of upa and PAI-1 in epithelial ovarian cancer].
Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
[TBL] [Abstract] [Full Text] [Related]
16. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.
Whitley BR; Beaulieu LM; Carter JC; Church FC
Gynecol Oncol; 2007 Feb; 104(2):470-9. PubMed ID: 17070899
[TBL] [Abstract] [Full Text] [Related]
17. Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors upa and PAI-1 in primary ovarian carcinoma.
Dorn J; Harbeck N; Kates R; Magdolen V; Grass L; Soosaipillai A; Schmalfeldt B; Diamandis EP; Schmitt M
Biol Chem; 2006 Aug; 387(8):1121-8. PubMed ID: 16895483
[TBL] [Abstract] [Full Text] [Related]
18. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B
Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158
[TBL] [Abstract] [Full Text] [Related]
19. Upregulation of bikunin in tumor-infiltrating macrophages as a factor of favorable prognosis in ovarian cancer.
Tanaka Y; Kobayashi H; Suzuki M; Kanayama N; Suzuki M; Terao T
Gynecol Oncol; 2004 Sep; 94(3):725-34. PubMed ID: 15350365
[TBL] [Abstract] [Full Text] [Related]
20. Analysis of potential prognostic factors in 111 patients with ovarian cancer.
Hornung R; Urs E; Serenella E; Edward W; Ursula S; Urs H; Daniel F
Cancer Lett; 2004 Mar; 206(1):97-106. PubMed ID: 15019165
[TBL] [Abstract] [Full Text] [Related]
[Next]
